The second bellwether trial against Sanofi-Aventis over its prescription chemotherapy drug Taxotere began today.
The trial in New Orleans is one of nearly 12,500 lawsuits coordinated in multidistrict litigation alleging that women who take Taxotere, a chemotherapy drug used to treat breast cancer, never grow back their hair, a side effect the U.S. Food and Drug Administration acknowledged in a labeling change in 2015. The first bellwether trial ended in a defense verdict in 2019.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]